IBRX Q3 2023 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$82,000-30.5% YoY

Gross Profit

$82,000100.0% margin

Operating Income

-$80M-97726.8% margin

Net Income

-$96M-116563.4% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+100.0%

Cash Flow

Operating Cash Flow

-$87M

Free Cash Flow

-$93M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$432M

Total Liabilities

$843M

Stockholders' Equity

-$412M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$82,000	$118,000	-30.5%
Gross Profit	$82,000	-$6M	+101.4%
Operating Income	-$80M	-$91M	+11.7%
Net Income	-$96M	-$111M	+13.8%